| Title: |
Biology, prognosis and response to therapy of breast carcinomas according to HER2 score |
| Authors: |
Ménard S; Balsari A; Tagliabue E; Camerini T; Casalini P; Bufalino R; Castiglioni F; Carcangiu ML; Gloghini A; Scalone S; Querzoli P; Lunardi M; Molino A; Mandarà M; Mottolese M; Marandino F; Venturini M; Bighin C; Cancello G; Montagna E; Perrone F; De Matteis A; Donadio M; Battelli N; Santinelli A; Pavesi L; Lanza A; Zito FA; Labriola A; Aiello RA; Caruso M; Zanconati F; Mustacchi G; Barbareschi M; Frisinghelli M; Russo R; Carrillo G; OMERO Group; SAPINO, Anna |
| Contributors: |
Ménard S; Balsari A; Tagliabue E; Camerini T; Casalini P; Bufalino R; Castiglioni F; Carcangiu ML; Gloghini A; Scalone S; Querzoli P; Lunardi M; Molino A; Mandarà M; Mottolese M; Marandino F; Venturini M; Bighin C; Cancello G; Montagna E; Perrone F; De Matteis A; Sapino A; Donadio M; Battelli N; Santinelli A; Pavesi L; Lanza A; Zito FA; Labriola A; Aiello RA; Caruso M; Zanconati F; Mustacchi G; Barbareschi M; Frisinghelli M; Russo R; Carrillo G; OMERO Group. |
| Publication Year: |
2008 |
| Collection: |
Università degli studi di Torino: AperTo (Archivio Istituzionale ad Accesso Aperto) |
| Subject Terms: |
HER2; HeceptTest; prognosi; therapy |
| Description: |
BACKGROUND: The standardization of the HER2 score and recent changes in therapeutic modalities points to the need for a reevaluation of the role of HER2 in recently diagnosed breast carcinoma. PATIENTS AND METHODS: A multicenter, retrospective study of 1794 primary breast carcinomas diagnosed in Italy in 2000/2001 and scored in HER2 four categories according to immunohistochemistry was conducted. RESULTS: Ductal histotype, vascular invasion, grade, MIB1 positivity, estrogen and progesterone receptor expression differed significantly in HER2 3+ tumors compared with the other categories. HER2 2+ tumors almost showed values intermediate between those of the negative and the 3+ subgroups. The characteristics of HER2 1+ tumors were found to be in between those of HER2 0 and 2+ tumors. With a median follow-up of 54 months, HER2 3+ status was associated with higher relapse rates in node-positive and node-negative subgroups, while HER2 2+ only in node positive. Analysis of relapses according to type of therapy provided evidence of responsiveness of HER2-positive tumors to chemotherapy, especially taxanes. CONCLUSIONS: The present prognostic significance of HER2 is correlated to receptor expression level and points to the need to consider HER2 2+ and HER2 3+ tumors as distinct diseases with different outcomes and specific features. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/18544559; info:eu-repo/semantics/altIdentifier/wos/WOS:000259581200006; volume:19; firstpage:1706; lastpage:1712; numberofpages:7; journal:ANNALS OF ONCOLOGY; http://hdl.handle.net/2318/59131; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-53049084124; http://annonc.oxfordjournals.org/cgi/content/full/19/10/1706 |
| DOI: |
10.1093/annonc/mdn369 |
| Availability: |
http://hdl.handle.net/2318/59131; https://doi.org/10.1093/annonc/mdn369; http://annonc.oxfordjournals.org/cgi/content/full/19/10/1706 |
| Rights: |
info:eu-repo/semantics/closedAccess |
| Accession Number: |
edsbas.479D209F |
| Database: |
BASE |